<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the complications of chronic lymphocytic leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the complications of chronic lymphocytic leukemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the complications of chronic lymphocytic leukemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kanti R Rai, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Stilgenbauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm) characterized by the progressive accumulation of functionally incompetent lymphocytes, which are usually monoclonal in origin.</p><p>CLL is considered to be identical (ie, one disease with different manifestations) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL), a clinically indolent non-Hodgkin lymphoma. The term CLL is used when the disease manifests primarily in the blood, whereas the term SLL is used when involvement is primarily nodal.</p><p>The major complications of CLL/SLL will be discussed here. The diagnosis of CLL/SLL and treatment of the underlying disorder are presented separately. The risk of infections and prevention of infections in patients with CLL are also discussed in detail separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1405.html" rel="external">"Prevention of infections in patients with chronic lymphocytic leukemia"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">INFECTION</span></p><p class="headingAnchor" id="H3"><span class="h2">Immune defects and spectrum of infections</span><span class="headingEndMark"> — </span>Patients with CLL/SLL have abnormal cellular and humoral-mediated immune responses due to quantitative and qualitative defects in immune effector cells. These defects can be due to the underlying disease process or to therapy used for treatment. This is described in more detail separately. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Immune defects'</a>.)</p><p>The spectrum of infections in patients with CLL/SLL has changed over the past several decades with the introduction of CLL/SLL therapies that have specific effects on immune function, particularly on cell-mediated immunity. The infectious complications seen in these patients have evolved in relation to the specific agents used and is discussed separately in relation to the various classes of CLL/SLL therapy. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Spectrum of infections'</a>.)</p><p class="headingAnchor" id="H3428917185"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>Given the high rate of infection and associated morbidity and mortality among patients with CLL/SLL, attempts have been made to decrease the rate of infection by using vaccines, intravenous immunoglobulin, prophylactic antimicrobials, and myeloid growth factors. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1405.html" rel="external">"Prevention of infections in patients with chronic lymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Evaluation of suspected infection</span><span class="headingEndMark"> — </span>Patients with CLL/SLL who develop signs of symptoms concerning for infection should undergo an initial evaluation that includes:</p><p class="bulletIndent1"><span class="glyph">●</span>A thorough general medical history and physical examination</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A complete blood cell count with differential, transaminases, bilirubin, electrolytes, blood urea nitrogen (BUN) and creatinine, blood cultures, sputum Gram stain and culture, and urine Gram stain and culture</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chest radiograph</p><p></p><p>If localizing signs or symptoms are present, other tests should be considered for further investigation. Lumbar puncture is not necessary routinely but should be performed in patients who have a change in mental status, headache, or other neurological symptoms. (See  <a class="medical medical_review" href="/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a>.)</p><p>Opportunistic infections should be considered in any patient who develops persistent fever or unexplained pulmonary infiltrates. For patients with unexplained or unresponsive pulmonary infiltrates, we advocate the use of bronchoscopy with bronchoalveolar lavage or transbronchial biopsy to identify opportunistic pathogens such as Aspergillus (or other fungi), cytomegalovirus, herpes simplex virus, <em>Pneumocystis jirovecii</em>, or mycobacterial infections. (See  <a class="medical medical_review" href="/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients"</a> and  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The management of infections in patients with CLL/SLL depends on the patient's risk factors for life-threatening infections (eg, neutropenia, recent therapy) and whether the patient appears septic or toxic at presentation.</p><p>Patients who are septic and/or have an absolute neutrophil count (ANC) less than 500 to 1000 cells/microL should be treated on an emergency basis with empiric broad spectrum coverage with activity against <em>Pseudomonas aeruginosa</em> and other gram-negative and gram-positive pathogens. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p>Patients who are not septic and have an ANC above 1000 cells/microL can often be treated with antibiotics directed at the most likely pathogen given the presenting signs and symptoms.</p><p>As an example, patients with signs and/or symptoms of a sinobronchial infection can often be treated with conventional antibiotics used for the general population. Dose adjustment may be needed due to drug interactions with some medications (eg, azoles, macrolides). Most patients respond to such treatment, but some patients develop chronic sinusitis that may require referral to an ear, nose, and throat specialist. (See  <a class="medical medical_review" href="/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"</a>.)</p><p>Herpes simplex and herpes zoster infection often complicate advanced stage disease. Treatment with antivirals should be instituted early. (See  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/8287.html" rel="external">"Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults", section on 'Treatment of HSV-1 infection'</a>.)</p><p class="headingAnchor" id="H148008801"><span class="h1">COLITIS AND HEPATOTOXICITY</span><span class="headingEndMark"> — </span>The phosphoinositide 3-kinase (PI3K) delta inhibitors <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a> and <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a> have been associated with serious, potentially fatal diarrhea and/or colitis in a minority of patients [<a href="#rid1">1</a>]. Diarrhea can occur at any time and the concurrent use of other drugs that cause diarrhea should be avoided. Idelalisib-associated diarrhea does not usually respond to antimotility agents. The package insert describes management by severity:</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate diarrhea (increase of 4 to 6 stools/day over baseline) – Continue treatment and monitor the severity of diarrhea at least weekly, until resolved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe diarrhea (increase of &gt;6 stools/day over baseline) or hospitalization – Hold treatment and monitor the severity of diarrhea, until resolved. Once resolved, <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a> may be resumed at a lower dose (100 mg twice daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening diarrhea – Discontinue treatment permanently. </p><p></p><p>More detailed recommendations for the evaluation and management of PI3K inhibitor-related diarrhea have been proposed by an expert panel [<a href="#rid2">2</a>]. These include the use of topical or systemic corticosteroids for severe diarrhea after the exclusion of infectious causes. Management of acute chemotherapy-related diarrhea is discussed separately. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea"</a>.)</p><p><a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">Idelalisib</a> has also been associated with fatal and/or serious hepatotoxicity. Close monitoring of liver function tests especially during the first three months of treatment is recommended. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'PI3K inhibitors'</a>.)</p><p class="headingAnchor" id="H148008815"><span class="h1">PNEUMONITIS</span><span class="headingEndMark"> — </span>Fatal and serious pneumonitis can occur in patients treated with PI3K inhibitors and, less commonly, with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> [<a href="#rid1">1,3</a>]. Pneumonitis should be suspected in patients taking one of these agents who develop pulmonary symptoms (cough, dyspnea, hypoxia), interstitial infiltrates on radiologic examination, and/or a decline in oxygen saturation by more than 5 percent. These agents should be withheld during the investigation of suspected pneumonitis. Pneumonitis thought to be due to these agents has been managed with glucocorticoids. These agents should be discontinued permanently in patients with any severity of symptomatic pneumonitis. <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> has also been reported to cause pneumonitis, cough, dyspnea, and pulmonary infiltrates. (See  <a class="medical medical_review" href="/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Idelalisib, duvelisib, and alpelisib'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">ANEMIA</span><span class="headingEndMark"> — </span>Anemia is a common complication of advanced CLL/SLL and it is often multifactorial. Causes of anemia in patients with CLL/SLL include:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal blood loss secondary to the use of corticosteroids, thrombocytopenia, mucositis or coagulopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Hypersplenism</p><p class="bulletIndent1"><span class="glyph">●</span>Marrow suppression secondary to the use of chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Marrow infiltration by advanced disease</p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic anemia (see <a class="local">'Autoimmune hemolytic anemia'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Red blood cell aplasia (see <a class="local">'Red cell aplasia'</a> below)</p><p></p><p>The initial evaluation of a patient with CLL/SLL who develops anemia should include a complete blood count (CBC) with red cell indices, white blood cell count with differential, platelet count, reticulocyte count, direct antiglobulin test (DAT), serum bilirubin, lactate dehydrogenase (LDH), haptoglobin, and a review of the peripheral blood smear. Further studies, including iron studies, a urine hemosiderin or bone marrow aspiration and biopsy may be required for further evaluation. (See  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Autoimmune hemolytic anemia</span><span class="headingEndMark"> — </span>The incidence of autoimmune hemolytic anemia (AIHA) in patients with CLL/SLL is difficult to determine with certainty. As many as one-third of patients with CLL/SLL may develop AIHA over the course of their illness unrelated to treatment modality [<a href="#rid4">4</a>], although most series suggest a rate in the range of 4 to 10 percent [<a href="#rid5">5,6</a>]. </p><p>Risk factors include increasing disease stage and unfavorable biologic features (eg, unmutated IGHV, 17p deletion, <em>TP53</em> mutation). The prevalence increases from a rate of approximately 4 percent in Binet stage A to 10 percent in stages B and C  (<a class="graphic graphic_table graphicRef80421 graphicRef56284" href="/d/graphic/80421.html" rel="external">table 1A-B</a>). The incidence does not appear to increase following CLL/SLL treatment with targeted therapies (eg, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>) [<a href="#rid7">7</a>]. While initial studies suggested that the incidence of AIHA may be higher following purine analog treatment, it does not appear to be increased when <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a> is used in combination with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and/or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. </p><p>The autoantibodies that cause AIHA can be produced by nonmalignant B cells or, less commonly, by the malignant CLL/SLL clone itself [<a href="#rid8">8,9</a>]. The mechanism is unknown and may be the result of interactions between the malignant CLL/SLL clone, abnormally functioning T cells, the microenvironment, and the larger immune system. </p><p class="headingAnchor" id="H14"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of AIHA is typically made in a patient with an isolated fall in hemoglobin and a positive direct antiglobulin (Coombs) test, indirect hyperbilirubinemia, reticulocytosis, reduced haptoglobin, and elevation of serum LDH. However, not all patients with AIHA will demonstrate these laboratory findings. In one study, only 18 percent of those patients with CLL/SLL and hemolytic anemia had a positive Coombs test [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Direct antiglobulin (Coombs) testing'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Management</span><span class="headingEndMark"> — </span>Patients with CLL/SLL who develop AIHA are treated with medical therapies similar to those used for other patients with AIHA [<a href="#rid11">11,12</a>]. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Initial management'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Red cell aplasia</span><span class="headingEndMark"> — </span>Pure red cell aplasia (PRCA) is characterized by the disappearance of red cell precursors from the bone marrow and a profound reduction in the absolute reticulocyte count [<a href="#rid13">13</a>]. The exact incidence of PRCA among patients with CLL/SLL is incompletely understood. Most studies have suggested that it is a rare complication of CLL/SLL, occurring in approximately 0.5 percent of patients. However, if this disorder is specifically sought with a bone marrow aspiration and absolute reticulocyte count, PRCA may be found in up to 6 percent of patients with CLL/SLL [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Identification</span><span class="headingEndMark"> — </span>The diagnosis of PRCA is made based on an evaluation of a peripheral blood smear and a bone marrow aspiration and biopsy. Before attributing the PRCA to an autoimmune phenomenon, the patient should be evaluated for viral infections which have been associated with PRCA and (pan)cytopenia in general. These include cytomegalovirus, Epstein-Barr virus, and parvovirus. (See  <a class="medical medical_review" href="/d/html/7120.html" rel="external">"Acquired pure red cell aplasia in adults", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Therapy</span><span class="headingEndMark"> — </span>The management of patients with PRCA includes the judicious use of red cell transfusions and immunosuppressants, such as <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and glucocorticoids. The majority of patients with CLL/SLL and PRCA will have a complete response to treatment with oral cyclosporine [<a href="#rid13">13,15</a>]. The usual dose is 10 to 14 mg/kg per day in two divided doses, with adjustment according to trough serum levels, response, and tolerance. In particular, renal and hepatic function and serum magnesium levels need to be closely monitored. Patients with refractory acquired PRCA may respond to therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/7120.html" rel="external">"Acquired pure red cell aplasia in adults", section on 'Management'</a>.)</p><p>In a series of 31 patients with CLL/SLL and anemia or thrombocytopenia of presumed autoimmune etiology (19 of whom had prior therapy for this complication), oral <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> (300 mg daily) resulted in responses in over 60 percent of patients [<a href="#rid17">17</a>]. The initial, maximal, and duration of response were three weeks, 10 weeks, and 10 months, respectively. Elevation of creatinine (≤grade II) was observed in six patients, requiring dose adjustment.</p><p>Transfusion of packed red cells is usually indicated in patients who are clinically symptomatic from severe anemia. The risks of transfusion in patients with CLL/SLL are similar to those in other patients. Transfusion reactions are not common in patients with CLL/SLL. Leukocyte-depleted and, in rare instances, washed red cell products should be considered for patients who have repeated episodes of transfusion reactions. Irradiated blood products have been used in severely immunosuppressed patients in an attempt to reduce the risk of transfusion-related graft-versus-host disease. We recommend the use of irradiated blood products in patients with CLL/SLL. (See  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions"</a> and  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Specialized modifications and products'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Chemotherapy-induced anemia</span><span class="headingEndMark"> — </span>The incidence of chemotherapy-induced anemia in patients with CLL/SLL depends on the chemotherapy regimen used. Management of symptomatic anemia from chemotherapy-induced myelosuppression includes transfusion of packed red blood cells and/or the administration of recombinant erythropoietin or <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin</a>. Issues surrounding the use of erythropoiesis-stimulating agents (ESAs) versus transfusion are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion"</a> and  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"</a>.)</p><p>As mentioned above, the risks of transfusion in patients with CLL/SLL are similar to those in other patients. Leukocyte-depleted and irradiated red cell products should be considered for all CLL/SLL patients. (See  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions"</a> and  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Specialized modifications and products'</a>.)</p><p>ESAs are rarely used in CLL/SLL. A decision to use them must take into account the degree of anemia, response to therapy, and risk of thromboembolism. While ESAs can increase hemoglobin levels and decrease transfusion requirements, they increase the risk for venous thromboembolism. In patients with "active disease," treatment is usually associated with a prompt improvement in hemoglobin levels, and it is better to avoid the use of ESAs. ESAs are reserved for patients with persistent anemia with a hemoglobin level of 10 g/dL or less [<a href="#rid18">18</a>]. The ESA should be discontinued if there is no improvement in the anemia and/or transfusion requirements within six to eight weeks. Furthermore, other causes of anemia (eg, MDS) should be excluded. Iron supplementation may improve responses in patients treated with an ESA with or without iron deficiency.</p><p class="headingAnchor" id="H20"><span class="h1">THROMBOCYTOPENIA</span><span class="headingEndMark"> — </span>Thrombocytopenia can occur at any time in the disease course of CLL/SLL. If it is present at the time of diagnosis, it is typically mild. A platelet count below 50,000/microL usually occurs only late in the disease. The causes of thrombocytopenia in patients with CLL/SLL include:</p><p class="bulletIndent1"><span class="glyph">●</span>Suppression of platelet production in the presence of extensive tumor burden</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune destruction</p><p class="bulletIndent1"><span class="glyph">●</span>Hypersplenism</p><p class="bulletIndent1"><span class="glyph">●</span>Infection (particularly sepsis and associated disseminated intravascular coagulation)</p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy</p><p></p><p>The initial evaluation of thrombocytopenia in a patient with CLL/SLL should include a complete blood count (CBC) and examination of the peripheral smear. The peripheral smear should be analyzed for an estimation of platelet numbers, morphology, presence or absence of platelet clumping, as well as evaluation of associated white and red blood cell changes. In patients with infections or fever, coagulation parameters should be checked, including the PT, aPTT, and fibrinogen. A bone marrow aspiration and biopsy can help to determine the underlying cause in difficult cases. (See  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Advanced disease</span><span class="headingEndMark"> — </span>Patients with thrombocytopenia due to advanced disease typically demonstrate extensive infiltration of the bone marrow on bone marrow aspiration and biopsy. Thrombocytopenia due to extensive tumor burden often improves with chemotherapy. However, if patients are refractory to the chemotherapy chosen, thrombocytopenia may be worsened by treatment. (See  <a class="medical medical_review" href="/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a> and  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Immune thrombocytopenia</span><span class="headingEndMark"> — </span>Clinically significant immune thrombocytopenia (ITP) develops in 2 to 5 percent of patients with CLL/SLL [<a href="#rid19">19</a>]. Up to one-third of cases will have concurrent autoimmune hemolytic anemia, the combination of which is referred to as Evan's syndrome. The diagnosis of ITP is suggested by a rapid, unexplained fall in platelets in the absence of bone marrow failure or hypersplenism. Bone marrow aspirate and biopsy demonstrates normal to increased bone marrow megakaryocytes. (See  <a class="medical medical_review" href="/d/html/6676.html" rel="external">"Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis"</a>.)</p><p>The treatment of ITP in the context of CLL/SLL is similar to that of patients with ITP who do not have CLL/SLL. Approximately half of patients will respond to initial therapy and 20 percent will have refractory disease despite trials of several agents [<a href="#rid17">17,20,21</a>]. Treatment options are presented in more detail separately. (See  <a class="medical medical_review" href="/d/html/6677.html" rel="external">"Initial treatment of immune thrombocytopenia (ITP) in adults"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Hypersplenism</span><span class="headingEndMark"> — </span>Hypersplenism refers to the sequestration of platelets in an enlarged spleen. (See  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Imaging and biopsy'</a>.)</p><p>The majority of patients with hypersplenism will have an improvement in their platelet count and decrease in their platelet transfusion requirements following splenectomy, whether or not they have splenic enlargement clinically [<a href="#rid22">22-24</a>]. Ideally, two to three weeks prior to splenectomy, patients should be vaccinated against pneumococcus, <em>Haemophilus influenzae </em>B, and meningococcus. In addition, some clinicians advocate lifelong penicillin (or equivalent) prophylaxis for pneumococcus due to uncertainty of immune response to vaccination. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Palliation of symptoms'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">PSYCHOLOGICAL DISTRESS</span><span class="headingEndMark"> — </span>A diagnosis of leukemia is an emotional challenge to patients. A discussion of the natural history of the disorder and positive reinforcement of the rapidly increasing range of treatment options will be sufficient to allay the fears of most patients. However, formal psychological counseling is appropriate for some patients to enable them to cope with the stress of knowing that they have leukemia. (See  <a class="medical medical_review" href="/d/html/4858.html" rel="external">"Patients with cancer: Overview of the clinical features and diagnosis of psychiatric disorders"</a> and  <a class="medical medical_review" href="/d/html/4853.html" rel="external">"Management of psychiatric disorders in patients with cancer"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SECOND CANCERS</span><span class="headingEndMark"> — </span>Several retrospective studies have suggested that patients with CLL/SLL have a higher risk of developing other hematologic and solid malignancies. The most common are the same as in the non-CLL/SLL population: lung, breast, colon, and prostate cancers. It is unknown how much of this increased risk is due to the underlying disease and accompanying chronic immunosuppression and how much is due to the treatments given. There have been no studies of cancer screening in patients with CLL/SLL. Patients with CLL/SLL should undergo age and sex appropriate screening measures for solid tumors. (See  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Cancer screening'</a>.)</p><p>In 1 to 10 percent of patients, CLL/SLL transforms into a clinically aggressive lymphoma (called Richter transformation or Richter syndrome) or prolymphocytic leukemia. In addition, patients treated for CLL/SLL can develop therapy-related myeloid neoplasms, presenting as a myelodysplastic syndrome or acute myeloid leukemia. In particular, fludarabine-containing regimens are associated with an increased risk of myelodysplastic syndrome [<a href="#rid25">25</a>]. These are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4728.html" rel="external">"Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4506.html" rel="external">"Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"</a>.)</p><p>Patients with CLL/SLL may also have a higher risk of developing secondary solid tumors [<a href="#rid25">25-35</a>]. The tumor types that have demonstrated increased rates have varied among studies.</p><p>The largest retrospective study was an analysis of 16,367 patients with CLL/SLL enrolled in the Surveillance, Epidemiology, and End Results (SEER) program and followed for an average of 5.2 years [<a href="#rid29">29</a>]. Eleven percent developed a second solid tumor, a rate that was significantly higher than that for the general population (odds ratio of 1.20, 95% CI 1.15-1.26). The highest excess rates were noted for Kaposi sarcoma, malignant melanoma, cancers of the larynx, and cancers of the lung.</p><p>Patients with CLL/SLL who develop a solid tumor may have inferior survival when compared with patients with solid tumors who do not have a pre-existing diagnosis of CLL/SLL.</p><p>An analysis of more than 2.3 million patients with cancers of the breast, colorectum, prostate, lung, kidney, pancreas, or ovary enrolled in the SEER program identified 4494 cases (0.19 percent) with a prior diagnosis of CLL/SLL [<a href="#rid36">36</a>]. After adjusting for age, sex, race, and disease stage, patients with pre-existing CLL/SLL had inferior overall survival when compared with those without CLL/SLL following a diagnosis of cancer of the breast (hazard ratio [HR] 1.70; 95% CI 1.51-1.91), colorectum (HR 1.65; 95% CI 1.53-1.79), or prostate (HR 1.92; 95% CI 1.73-2.13). This inferior survival remained when CLL/SLL-related deaths were excluded.</p><p>It is unknown why patients with CLL/SLL who have a solid tumor appear to have worse survival. Solid tumors that develop in patients with CLL/SLL may be biologically different from those that develop in the general population. This could be related to the patient's underlying genetics or the impact of prior therapy for CLL/SLL. Alternatively, patients with CLL/SLL may be less able to tolerate preferred treatment strategies due to underlying cytopenias or immunosuppression. Further study is needed to determine whether the approach to treatment should differ from the standard approach.</p><p class="headingAnchor" id="H26"><span class="h1">LEUKOSTASIS</span><span class="headingEndMark"> — </span>Leukostasis is a medical emergency characterized by an extremely elevated white blood cell (WBC) count and symptoms of decreased tissue perfusion. While a significant proportion of patients with CLL/SLL present with a high WBC count, symptoms of leukostasis are rare unless the WBC count exceeds 400 x 10<sup>9</sup>/L (400,000/microL). (See  <a class="medical medical_review" href="/d/html/4522.html" rel="external">"Hyperleukocytosis and leukostasis in hematologic malignancies"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">TUMOR LYSIS SYNDROME</span><span class="headingEndMark"> — </span>Tumor lysis syndrome (TLS) is characterized by hyperphosphatemia, hypocalcemia, hyperkalemia, and renal insufficiency. The inciting cause seems to be release of large amounts of phosphate and other products of cell destruction from lysed cells, which coprecipitates with calcium in the kidneys, leading to hypocalcemia and sometimes to oliguric renal failure. Hyperuricemia further contributes to this problem. The incidence of TLS in CLL/SLL varies with the treatment given. Some regimens require prophylaxis for TLS while others do not. The diagnosis and treatment of TLS is presented in more detail separately. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p class="headingAnchor" id="H4281728378"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120614.html" rel="external">"Society guideline links: Chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p class="headingAnchor" id="H8541315"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/687.html" rel="external">"Patient education: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune defects</strong> – Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) commonly develop complications associated with their intrinsic immune dysfunction resulting in immunodeficiency and autoimmune disorders. The most common complications are infection, anemia, and thrombocytopenia. </p><p></p><p class="bulletIndent1">Patients with CLL/SLL have abnormal cellular and humoral-mediated immune responses due to quantitative and qualitative defects in immune effector cells. These defects can be due to the underlying disease process or to therapy used for treatment. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Immune defects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment of infection</strong> – Given the high rate of infection and associated morbidity and mortality, attempts have been made to decrease the rate of infection by using vaccines, intravenous immunoglobulin, prophylactic antimicrobials, and myeloid growth factors. The approach to prophylaxis depends upon the type of treatment planned and its associated immune dysfunction  (<a class="graphic graphic_table graphicRef95493" href="/d/graphic/95493.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef95619" href="/d/graphic/95619.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/1405.html" rel="external">"Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Antimicrobial prophylaxis'</a>.)</p><p></p><p class="bulletIndent1">The management of infections in patients with CLL/SLL depends on the patient's risk factors for life-threatening infections (eg, neutropenia, recent therapy) and whether they appear septic or toxic at presentation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are septic and/or have an absolute neutrophil count less than 500 to 1000 cells/microL should be treated emergently with empiric broad spectrum coverage. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are not septic and have an absolute neutrophil count above 1000 cells/microL can often be treated with antibiotics directed at the most likely pathogen given the presenting signs and symptoms. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – Anemia is a common complication of advanced CLL/SLL and may be due to hypersplenism, marrow infiltration, gastrointestinal blood loss, chemotherapy-induced bone marrow suppression, (autoimmune) hemolysis, or red blood cell aplasia. Treatment should be directed at the underlying cause. (See <a class="local">'Anemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – Causes of thrombocytopenia in patients with CLL/SLL include extensive tumor burden, autoimmune destruction, and hypersplenism. Treatment should be directed at the underlying cause. (See <a class="local">'Thrombocytopenia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor lysis syndrome</strong> – Tumor lysis syndrome is a rare but potentially life-threatening complication characterized by hyperphosphatemia, hypocalcemia, hyperkalemia, and renal insufficiency. The incidence of tumor lysis syndrome varies with the treatment given and some regimens require prophylaxis for tumor lysis syndrome. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second cancers</strong> – Patients with CLL/SLL may have a higher risk of developing other hematologic and solid malignancies. Patients with CLL/SLL should undergo age- and sex-appropriate screening. (See <a class="local">'Second cancers'</a> above.)</p><p></p><p class="headingAnchor" id="H1604652"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The<strong> </strong>UpToDate editorial staff acknowledges Michael J Keating, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf (Accessed on August 11, 2014).</li><li><a class="nounderline abstract_t">Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 2015; 56:2779.</a></li><li><a class="nounderline abstract_t">Mato AR, Islam P, Daniel C, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood 2016; 127:1064.</a></li><li><a class="nounderline abstract_t">Bergsagel DE. The chronic leukemias: a review of disease manifestations and the aims of therapy. Can Med Assoc J 1967; 96:1615.</a></li><li><a class="nounderline abstract_t">Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67:235.</a></li><li><a class="nounderline abstract_t">Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95:2786.</a></li><li><a class="nounderline abstract_t">Vitale C, Salvetti C, Griggio V, et al. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood 2021; 137:3507.</a></li><li><a class="nounderline abstract_t">Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 2011; 96:752.</a></li><li><a class="nounderline abstract_t">Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol 2014; 89:1055.</a></li><li><a class="nounderline abstract_t">Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol 2007; 136:800.</a></li><li><a class="nounderline abstract_t">Gribben JG. How I treat CLL up front. Blood 2010; 115:187.</a></li><li><a class="nounderline abstract_t">Hodgson K, Ferrer G, Pereira A, et al. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011; 154:14.</a></li><li><a class="nounderline abstract_t">Chikkappa G, Pasquale D, Phillips PG, et al. Cyclosporin-A for the treatment of pure red cell aplasia in a patient with chronic lymphocytic leukemia. Am J Hematol 1987; 26:179.</a></li><li><a class="nounderline abstract_t">Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80.</a></li><li><a class="nounderline abstract_t">Tura S, Finelli C, Bandini G, et al. Cyclosporin A in the treatment of CLL associated PRCA and bone marrow hypoplasia. Nouv Rev Fr Hematol 1988; 30:479.</a></li><li><a class="nounderline abstract_t">Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002; 99:1092.</a></li><li><a class="nounderline abstract_t">Cortes J, O'Brien S, Loscertales J, et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 2001; 92:2016.</a></li><li><a class="nounderline abstract_t">Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv 2019; 3:1197.</a></li><li><a class="nounderline abstract_t">Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008; 111:1110.</a></li><li><a class="nounderline abstract_t">Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008; :450.</a></li><li><a class="nounderline abstract_t">Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100:2260.</a></li><li><a class="nounderline abstract_t">Seymour JF, Cusack JD, Lerner SA, et al. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 1997; 15:52.</a></li><li><a class="nounderline abstract_t">Delpero JR, Gastaut JA, Letreut YP, et al. The value of splenectomy in chronic lymphocytic leukemia. Cancer 1987; 59:340.</a></li><li><a class="nounderline abstract_t">Ferrant A, Michaux JL, Sokal G. Splenectomy in advanced chronic lymphocytic leukemia. Cancer 1986; 58:2130.</a></li><li><a class="nounderline abstract_t">da Cunha-Bang C, Rostgaard K, Andersen MA, et al. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. Br J Haematol 2021; 193:339.</a></li><li><a class="nounderline abstract_t">Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009; 27:904.</a></li><li><a class="nounderline abstract_t">Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232:267.</a></li><li><a class="nounderline abstract_t">Greene MH, Hoover RN, Fraumeni JF Jr. Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. J Natl Cancer Inst 1978; 61:337.</a></li><li><a class="nounderline abstract_t">Hisada M, Biggar RJ, Greene MH, et al. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98:1979.</a></li><li><a class="nounderline abstract_t">Royle JA, Baade PD, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 2011; 105:1076.</a></li><li><a class="nounderline abstract_t">Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84:1422.</a></li><li><a class="nounderline abstract_t">Schöllkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007; 121:151.</a></li><li><a class="nounderline abstract_t">Velez NF, Karia PS, Vartanov AR, et al. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol 2014; 150:280.</a></li><li><a class="nounderline abstract_t">Lam CJ, Curtis RE, Dores GM, et al. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. J Clin Oncol 2015; 33:3096.</a></li><li><a class="nounderline abstract_t">Zheng G, Chattopadhyay S, Sud A, et al. Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. Br J Haematol 2019; 185:232.</a></li><li><a class="nounderline abstract_t">Solomon BM, Rabe KG, Slager SL, et al. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 2013; 31:930.</a></li></ol></div><div id="topicVersionRevision">Topic 4504 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf (Accessed on August 11, 2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25726955" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of adverse events associated with idelalisib treatment: expert panel opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702066" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5338329" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The chronic leukemias: a review of disease manifestations and the aims of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3499930" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10779422" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33651883" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242190" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic lymphocytic leukemia and autoimmunity: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24912821" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autoimmune cytopenias in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17341265" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19850738" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : How I treat CLL up front.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21534942" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3116843" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cyclosporin-A for the treatment of pure red cell aplasia in a patient with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482530" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3146746" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cyclosporin A in the treatment of CLL associated PRCA and bone marrow hypoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807020" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11596014" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30971397" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986663" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19074125" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Disease-specific complications of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200396" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996124" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Case/control study of the role of splenectomy in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3802020" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The value of splenectomy in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3756828" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Splenectomy in advanced chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570184" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114699" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/47401" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Subsequent neoplasia in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/277720" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11535538" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Solid tumors after chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21847118" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1512794" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Second cancers in patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17351903" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk of second cancer after chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24429548" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240221" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706458" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341508" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
